Precision BioSciences is developing mulitple DNE therapeutics targeted to enable the precise in situ correction of genes responsible for human disease.

More about BioTherapeutics >>

Engineered DNE meganucleases are being used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics.

More about BioTools >>

Custom DNE meganucleases produced by Precision BioSciences enable site-specific engineering of row crops and biofuel feedstocks.

More about PlantSciences >>

Recent News:

05.06.2013

Precision BioSciences Wins Patent Infringement Lawsuit against Cellectis

02.19.2013

Precision BioSciences Awarded Patent for Genetically Modifying Cells

More News

Featured Publication:

04.06.2010

Precision BioSciences and DuPont Detail Technology Efficacy in The Plant Journal

More Publications